regard
sampl
data
share
recogn
import
global
influenza
surveil
respons
system
gisr
pandem
influenza
prepared
pip
framework
well
global
initi
share
influenza
data
gisaid
berlin
declar
health
minist
may
initi
time
rel
littl
detail
knowledg
virus
structur
mechan
infect
ecolog
interrelationship
among
influenza
virus
infect
human
anim
research
high
prioriti
method
viru
detect
analysi
antigen
properti
also
fundament
virolog
properti
viru
mani
advanc
understand
influenza
made
close
associ
networkth
free
share
virus
inform
provid
vital
resourc
research
commun
thu
revel
protein
composit
viru
segment
natur
viru
genom
structur
sequenc
relationship
segment
relat
genet
reassort
antigen
relationship
anim
human
influenza
virus
basi
pandem
close
associ
work
member
network
cc
particular
elucid
crystal
structur
haemagglutinin
ha
provid
first
clear
understand
molecular
level
antigen
drift
differ
receptor
specif
human
anim
virus
relat
host
rang
restrict
mechan
viru
entri
cell
gener
mechan
membran
fusion
notabl
spinoff
research
resist
immun
infect
discoveri
interferon
uncov
peptid
basi
cellmedi
immun
scientif
excel
within
gisr
provid
intellectu
author
credibl
confid
verac
biannual
recommend
vaccin
composit
also
proceduresmethod
guidanc
interpret
tool
develop
anticip
risk
season
antigen
genet
variant
emerg
zoonot
infect
monitor
antivir
resist
network
also
close
align
fundament
interest
mechan
antivir
action
emerg
resist
thu
studi
resist
amantadin
reveal
target
novel
proton
channel
emerg
resist
vi
essenti
aspect
network
coordin
respons
gip
effect
rapid
collat
share
inform
via
flunet
virolog
data
fluid
epidemiolog
data
includ
viru
genet
sequenc
data
associ
inform
well
share
virus
refer
reagent
best
promot
time
share
genet
sequenc
data
gsd
prepubl
result
gisaid
data
share
mechan
essenc
databas
access
agreement
daa
govern
share
data
databas
daa
enshrin
code
conduct
provid
user
data
protect
ownership
data
make
freeli
avail
proviso
user
acknowledg
sourc
data
appropri
engag
origin
data
collabor
spirit
gisr
manner
consist
origin
intent
effect
demonstr
prompt
releas
genet
sequenc
first
case
zoonot
infect
china
enabl
rapid
product
synthet
biolog
candid
vaccin
viru
within
week
ensur
avail
latest
data
biannual
vaccin
consult
meet
vcm
close
align
principl
underli
gisaid
share
mechan
seven
key
principl
data
share
public
health
emerg
enunci
recent
global
research
collabor
infecti
diseas
prepared
glopidr
illustr
gisr
lead
way
implement
innov
mechan
procedur
gisaid
also
trustbas
system
integr
gsd
clinic
virolog
epidemiolog
data
take
advantag
latest
advanc
rapid
gene
sequenc
technolog
serv
good
exampl
share
gsd
relat
public
health
emerg
perhap
serv
exampl
pathogen
ebola
zika
virus
crucial
aspect
gisr
part
success
meet
strict
timelin
vaccin
viru
select
manufactur
qualiti
control
vaccin
prior
distribut
process
take
month
thu
develop
assist
interpret
uptod
data
anticip
potenti
futur
antigen
chang
like
benefici
avoid
mismatch
vaccin
circul
strain
reduc
vaccin
effect
asid
iron
technic
advanc
molecular
characteris
antigen
characteris
virus
becom
difficult
due
chang
specif
affin
receptor
bind
consequ
agglutin
red
blood
cell
differ
speci
addit
chang
antigen
conclus
result
antigen
relationship
longer
guarante
simpl
haemagglutin
inhibit
hi
test
antigen
characteris
reli
complementari
result
neutralis
assay
much
learn
mechan
ha
bind
differ
receptor
aviananim
human
cell
variou
avian
subtyp
virus
isol
infect
human
indic
affin
type
receptor
may
repres
intermedi
acquisit
humantohuman
transmiss
howev
chang
would
requir
environ
would
conduc
chang
ha
viru
protein
effect
effici
humantohuman
transmiss
simpli
known
thu
tool
influenza
pandem
risk
assess
irat
cdc
tipra
provid
compar
assess
perceiv
pandem
threat
zoonot
infect
term
sever
base
eg
casefat
ratio
likelihood
base
frequenc
human
infect
characterist
viru
assess
limit
predict
capac
virus
capac
transmit
respiratori
droplet
ferret
increas
transmiss
infect
peopl
yet
detect
even
largest
outbreak
emerg
highli
pathogen
avian
influenza
pathotyp
nevertheless
structur
framework
upon
base
assess
zoonot
virus
imperfect
provid
mechan
prioritis
risk
associ
specif
virus
doubt
enhanc
collabor
anim
health
human
health
sector
one
health
banner
also
help
optimis
avail
use
inform
clear
lack
fundament
knowledg
predict
likelihood
particular
subtyp
could
caus
pandem
anoth
differ
viru
caus
latest
pandem
novel
subtyp
differ
alreadi
circul
emphasis
adventiti
natur
emerg
pandem
viru
number
differ
subtyp
virus
transfer
pig
point
predilect
avian
virus
mammalian
transmiss
moreov
recent
sporad
human
infect
swine
variant
virus
beg
question
extent
pandem
virus
recycl
nevertheless
persist
circul
subtyp
almost
year
attest
resili
abil
continu
adapt
human
popul
pandem
threat
also
stimul
gip
becom
one
hand
gisr
undergon
revolut
introduct
molecular
genet
techniqu
recent
year
continu
transform
capabl
increas
introduct
ng
multiplex
molecular
platform
high
throughput
pointof
care
format
rapid
highli
sensit
specif
diagnosi
respiratori
tract
pathogen
hand
strainspecif
inactiv
vaccin
use
essenc
chang
littl
decad
sinc
introduct
year
ago
applic
synthet
biolog
potenti
tailor
improv
yield
high
growthyield
reassort
remov
exampl
undesir
substrateselect
chang
season
vaccin
seed
virus
given
substanti
lead
time
lack
avail
vaccin
ahead
first
wave
pandem
major
effort
develop
new
univers
vaccin
vaccin
strategi
stimul
broadli
reactiv
antibodi
conserv
epitop
surfac
protein
exampl
ha
stalk
na
cellmedi
immun
intern
protein
confer
protect
broader
rang
influenza
subtyp
least
differ
antigen
variant
within
subtyp
erl
requir
least
reevalu
correl
immun
altern
vaccin
potenc
method
moreov
licensur
new
antivir
exampl
target
viru
polymeras
therapeut
monoclon
antibodi
target
exampl
ha
stalk
requir
applic
new
phenotyp
assay
complement
molecular
marker
resist
threat
highli
pathogen
avian
influenza
viru
caus
zoonot
infect
develop
pandem
akin
caught
imagin
galvanis
global
respons
one
outcom
pip
framework
institut
bolster
fair
transpar
benefit
global
system
import
howev
recognis
awar
potenti
futur
impact
chang
network
larg
autonom
selffinanc
member
state
year
includ
formal
arrang
receiv
addit
financi
support
pip
partnership
contribut
amount
half
estim
run
cost
gisr
involv
behalf
member
state
directli
formal
share
ivpp
virus
given
success
global
influenza
programm
crucial
respons
ensur
addit
resourc
use
best
advantag
synergist
manner
strengthen
gisr
umbrella
gip
enabl
countri
meet
ihr
respons
promot
benefit
share
initi
well
ensur
gisr
extens
complementari
scientif
expertis
collabor
etho
remain
fulli
engag
benefit
global
health
secur
gisr
heart
respons
influenza
improv
vaccin
includ
quest
univers
flu
vaccin
antivir
essenti
improv
world
capabl
overal
effect
control
diseas
gisr
broad
vision
watch
eye
gip
continu
provid
leadership
interact
global
partner
implement
technolog
advanc
better
understand
factor
influenc
adapt
potenti
interspeci
transmiss
virus
host
respons
human
infect
essenti
retain
fundament
characterist
collabor
etho
gisr
evolv
global
influenza
programm
frontlin
defenc
influenza
form
preemin
exampl
integr
global
system
combat
infecti
diseas
http
